Natera's Signatera test linked to survival benefit in colon cancer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St falls as tech earnings spark AI spending worries; oil hits $100
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Dollar hits new 40-year high versus yen, euro lower after ECB decision
Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer
July 6, 2026 6:00 AM EDTNewly published study shows Signatera MRD-positive patients lived longer with adjuvant chemotherapy, while MRD-negative patients saw no significant benefit
First predictive data for overall survival from GALAXY trial in patients with oligo-metastatic CRC in the liver
AUSTIN, Texas--(BUSINESS... More
